Cancer immunology, immunotherapy : CII最新文献_第5页

Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma. 结直肠癌患者循环淋巴细胞亚群的改变。

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-08-01 Epub Date: 2021-12-20 DOI: 10.1007/s00262-021-03127-8

Johanna Waidhauser, Pia Nerlinger, Tim Tobias Arndt, Stefan Schiele, Florian Sommer, Sebastian Wolf, Phillip Löhr, Stefan Eser, Gernot Müller, Rainer Claus, Bruno Märkl, Andreas Rank

{"title":"Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma.","authors":"Johanna Waidhauser, Pia Nerlinger, Tim Tobias Arndt, Stefan Schiele, Florian Sommer, Sebastian Wolf, Phillip Löhr, Stefan Eser, Gernot Müller, Rainer Claus, Bruno Märkl, Andreas Rank","doi":"10.1007/s00262-021-03127-8","DOIUrl":"https://doi.org/10.1007/s00262-021-03127-8","url":null,"abstract":"Introduction: Cellular immune response to cancer is known to be of great importance for tumor control. Moreover, solid tumors influence circulating lymphocytes, which has been shown for several types of cancer. In our prospective study we elucidate changes in lymphocyte subsets in patients with colorectal carcinoma compared to healthy volunteers.Methods: Flow cytometry was performed at diagnosis of colon carcinoma to analyze B cells, T cells and NK cells including various subtypes of each group. Univariate and multivariate analyses including age, gender, tumor stage, sidedness and microsatellite instability status (MSI) were performed.Results: Forty-seven patients and 50 healthy volunteers were included. Median age was 65 years in patients and 43 years in the control group. Univariate analysis revealed lower total lymphocyte counts, lower CD4 + cells, CD8 + cells, B cells and NKs including various of their subsets in patients. In multivariate analysis patients had inferior values of B cells, CD4 + cells and NK cells and various subsets, regardless of age and gender. Naïve, central memory and HLADR + CD8 + cells showed an increase in patients whereas all other altered subsets declined. MSI status had no influence on circulating lymphocytes except for higher effector memory CD8 + cells in MSI-high patients. Localization in the left hemicolon led to higher values of total cytotoxic T cells and various T cell subsets.Conclusion: We found significant changes in circulating lymphocyte subsets in colon carcinoma patients, independent of physiological alterations due to gender or age. For some lymphocyte subsets significant differences according to tumor localization or MSI-status could be seen.","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"1937-1947"},"PeriodicalIF":5.8,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39853953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer. TGF-β调控结直肠癌中单核髓源性抑制细胞的表型和功能。

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-07-01 Epub Date: 2021-11-02 DOI: 10.1007/s00262-021-03081-5

Luciana Gneo, Nagy Rizkalla, Rahul Hejmadi, Francis Mussai, Carmela de Santo, Gary Middleton

{"title":"TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer.","authors":"Luciana Gneo, Nagy Rizkalla, Rahul Hejmadi, Francis Mussai, Carmela de Santo, Gary Middleton","doi":"10.1007/s00262-021-03081-5","DOIUrl":"https://doi.org/10.1007/s00262-021-03081-5","url":null,"abstract":"Background: Monocytic myeloid-derived suppressor cells (M-MDSCs) are significantly expanded in the blood of colorectal cancer (CRC) patients. However, their presence and underlying mechanisms in the tumour microenvironment of CRC have not been examined in detail.Methods: Tumour tissues and peripheral blood from CRC patients were analysed for the presence of M-MDSCs. The mechanisms of suppression were analysed by blocking pathways by which MDSCs abrogate T cell proliferation. Co-culture of CRC cells with monocytes were performed with and without cytokine blocking antibodies to determine the mechanism by which CRC cells polarise monocytes. Multi-spectral IHC was used to demonstrate the intra-tumoral location of M-MDSCs.Results: Tumour tissues and blood of CRC patients contain M-MDSCs which inhibit T cell proliferation. Whilst inhibition of arginase and nitric oxide synthase 2 fail to rescue T cell proliferation, blockade of IL-10 released by these HLA-DR- cells abrogates the suppresivity of M-MDSCs. Tumour conditioned media (TCM) significantly reduces HLA-DR expression, increases IL-10 release from monocytes and causes them to become suppressive. TGF-β is highly expressed in the TCM and accumulates in the plasma. TGF-β reduces HLA-DR expression and drives monocyte immunosuppressivity. The invasive margin of CRC is enriched in CD14+ HLA-DR- cells in close proximity to T cells.Conclusions: Our study demonstrates the cross-talk between CRC cells, M-MDSCs and T cells. Characterisation of CRC M-MDSCs point to therapeutic avenues to target these cells in addition to TGF-β blockade.","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"1583-1596"},"PeriodicalIF":5.8,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39836738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Redirecting host preexisting influenza A virus immunity for cancer immunotherapy. 重定向宿主先前存在的甲型流感病毒免疫用于癌症免疫治疗。

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-07-01 Epub Date: 2021-11-03 DOI: 10.1007/s00262-021-03099-9

Bharat K R Chaganty, Songbo Qiu, Yang Lu, Gabriel Lopez-Berestein, Bulent Ozpolat, Zhen Fan

{"title":"Redirecting host preexisting influenza A virus immunity for cancer immunotherapy.","authors":"Bharat K R Chaganty, Songbo Qiu, Yang Lu, Gabriel Lopez-Berestein, Bulent Ozpolat, Zhen Fan","doi":"10.1007/s00262-021-03099-9","DOIUrl":"https://doi.org/10.1007/s00262-021-03099-9","url":null,"abstract":"We tested the concept that host preexisting influenza A virus immunity can be redirected to inhibit tumor growth and metastasis through systemic administration of influenza A virus-related peptides to targeted tumors. Mice infected with influenza A virus strain A/Puerto Rico/8/34 (PR8) were used as a model of a host with preexisting viral immunity. The extent to which preexisting influenza A immunity in PR8-immunized mice can be redirected to inhibit tumor growth and metastasis was first examined by ectopic expression of influenza A nucleoprotein (NP) and hemagglutinin (HA) in syngeneic mammary tumor cells via lentiviral transduction. Then, the feasibility of implementing this strategy using a systemic therapy approach was assessed by systemic delivery of major histocompatibility complex class I (MHC-I)-compatible peptides to targeted mammary tumors overexpressing human epidermal growth factor receptor-2 (HER2) in mice using a novel HER2-targeting single-lipid nanoparticle (SLNP). Our results show that preexisting influenza A immunity in PR8-immunized mice could be quickly redirected to syngeneic tumors expressing influenza A NP and HA, leading to strong inhibition of tumor growth and metastasis and improvement of survival compared to the findings in antigen-naïve control mice. MHC-I-compatible peptides could be delivered to targeted mammary tumors in mice using the HER2-targeting SLNP for antigen presentation, which subsequently redirected preexisting influenza A immunity to the tumors to exert antitumor activities. In conclusion, preexisting influenza A immunity can be repurposed for cancer immunotherapy through systemic delivery of influenza A-related peptides to targeted tumors. Further development of the strategy for clinical translation is warranted.","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"1611-1623"},"PeriodicalIF":5.8,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39586837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens. R848和poly(I:C)激活的dc可诱导针对病毒和肿瘤相关抗原的抗原特异性免疫反应。

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-07-01 Epub Date: 2021-11-25 DOI: 10.1007/s00262-021-03109-w

Gerulf Hänel, Caroline Angerer, Katja Petry, Felix S Lichtenegger, Marion Subklewe

{"title":"Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens.","authors":"Gerulf Hänel, Caroline Angerer, Katja Petry, Felix S Lichtenegger, Marion Subklewe","doi":"10.1007/s00262-021-03109-w","DOIUrl":"https://doi.org/10.1007/s00262-021-03109-w","url":null,"abstract":"Monocyte-derived Dendritic cells (DCs) have successfully been employed to induce immune responses against tumor-associated antigens in patients with various cancer entities. However, objective clinical responses have only been achieved in a minority of patients. Additionally, generation of GMP-compliant DCs requires time- and labor-intensive cell differentiation. In contrast, Blood DCs (BDCs) require only minimal ex vivo handling, as differentiation occurs in vivo resulting in potentially better functional capacities and survival. We aimed to identify a protocol for optimal in vitro activation of BDCs including the three subsets pDCs, cDC1s, and cDC2s. We evaluated several TLR ligand combinations and demonstrated that polyinosinic:polycytidylic acid [poly(I:C)] and R848, ligands for TLR3 and TLR7/8, respectively, constituted the optimal combination for inducing a positive co-stimulatory profile in all BDC subsets. In addition, TLR3 and TLR7/8 activation led to high secretion of IFN-α and IL-12p70. Simultaneous as opposed to separate tailored activation of pDCs and cDCs increased immunostimulatory capacities, suggesting that BDC subsets engage in synergistic cross-talk during activation. Stimulation of BDCs with this protocol resulted in enhanced migration, high NK-cell activation, and potent antigen-specific T-cell induction.We conclude that simultaneous activation of all BDC subsets with a combination of R848 + poly(I:C) generates highly immunostimulatory DCs. These results support further investigation and clinical testing, as standalone or in conjunction with other immunotherapeutic strategies including adoptive T-cell transfer and checkpoint inhibition.","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"1705-1718"},"PeriodicalIF":5.8,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39658421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies. 自体修饰B细胞的高效过继转移:一种新的人源化平台小鼠模型，用于测试B细胞重编程疗法。

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-07-01 Epub Date: 2021-11-08 DOI: 10.1007/s00262-021-03101-4

Audrey Page, Emilie Laurent, Didier Nègre, Caroline Costa, Véronique Pierre, Thierry Defrance, François-Loïc Cosset, Floriane Fusil

{"title":"Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies.","authors":"Audrey Page, Emilie Laurent, Didier Nègre, Caroline Costa, Véronique Pierre, Thierry Defrance, François-Loïc Cosset, Floriane Fusil","doi":"10.1007/s00262-021-03101-4","DOIUrl":"https://doi.org/10.1007/s00262-021-03101-4","url":null,"abstract":"Here, we report a novel experimental setup to perform adoptive transfer of gene-edited B cells using humanized immune system mice by infusing autologous HIS mouse-derived human B cells \"educated\" in a murine context and thus rendered tolerant to the host. The present approach presents two advantages over the conventional humanized PBMC mouse models: (i) it circumvents the risk of xenogeneic graft-versus-host reaction and (ii) it mimics more closely human immune responses, thus favoring clinical translation. We show that the frequencies and numbers of transduced B cells in recipient's spleens one week post-transfer are within the range of the size of the pre-immune B cell population specific for a given protein antigen in the mouse. They are also compatible with the B cell numbers required to elicit a sizeable immune response upon immunization. Altogether, our findings pave the way for future studies aiming at assessing therapeutic interventions involving B cell reprogramming for instance by an antibody transgene in a \"humanized\" hematopoietic setting.","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"1771-1775"},"PeriodicalIF":5.8,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39599501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells. 人卵巢癌细胞内质网应激诱导钙调钙蛋白的释放和结合。

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-07-01 Epub Date: 2021-11-20 DOI: 10.1007/s00262-021-03072-6

Trefa M Abdullah, Jacqueline Whatmore, Edwin Bremer, Rimantas Slibinskas, Marek Michalak, Paul Eggleton

{"title":"Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells.","authors":"Trefa M Abdullah, Jacqueline Whatmore, Edwin Bremer, Rimantas Slibinskas, Marek Michalak, Paul Eggleton","doi":"10.1007/s00262-021-03072-6","DOIUrl":"https://doi.org/10.1007/s00262-021-03072-6","url":null,"abstract":"Background: Calreticulin (CRT) is an endoplasmic reticulum (ER) chaperone, but can appear surface bound on cancers cells, including ovarian cancers (OC). We investigated at what stage of cell viability, CRT appeared associated with surface of human OC cells. CRT on pre-apoptotic tumour cells is thought to initiate their eradication via a process termed immunogenic cell death (ICD).Methods: We treated OC cells with the chemotherapeutic-doxorubicin (DX) known to induce translocation of CRT to some tumour cell surfaces, with and without the ER stressor-thapsigargin (TG)-and/or an ER stress inhibitor-TUDCA. We monitored translocation/release of CRT in pre-apoptotic cells by flow cytometry, immunoblotting and ELISA. We investigated the difference in binding of FITC-CRT to pre-apoptotic, apoptotic and necrotic cells and the ability of extracellular CRT to generate immature dendritic cells from THP-1 monocytes.Results: Dx-treatment increased endogenously released CRT and extracellular FITC_CRT binding to human pre-apoptotic OC cells. DX and TG also promoted cell death in OC cells which also increased CRT release. These cellular responses were significantly inhibited by TUDCA, suggesting that ER stress is partially responsible for the changes in CRT cellular distribution. Extracellular CRT induces maturation of THP-1 towards a imDC phenotype, an important component of ICD.Conclusion: Collectively, these cellular responses suggest that ER stress is partially responsible for the changes in CRT cellular distribution. ER-stress regulates in part the release and binding of CRT to human OC cells where it may play a role in ICD.","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"1655-1669"},"PeriodicalIF":5.8,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39751345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy. 原位注射CpG/αOX40/cGAMP刺激α pd -1耐药恶性肿瘤的强大免疫应答。

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-07-01 Epub Date: 2021-11-03 DOI: 10.1007/s00262-021-03095-z

Luya Cai, Xuedan Du, Cheng Zhang, Shanshan Yu, Lixiao Liu, Jinduo Zhao, Ye Zhao, Chunhong Zhang, Jinting Wu, Bin Wang, Yingyu Chen, Xiaoping Su, Xiaojian Yan, Wenfeng Li

{"title":"Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy.","authors":"Luya Cai, Xuedan Du, Cheng Zhang, Shanshan Yu, Lixiao Liu, Jinduo Zhao, Ye Zhao, Chunhong Zhang, Jinting Wu, Bin Wang, Yingyu Chen, Xiaoping Su, Xiaojian Yan, Wenfeng Li","doi":"10.1007/s00262-021-03095-z","DOIUrl":"https://doi.org/10.1007/s00262-021-03095-z","url":null,"abstract":"Recently, the emergence of immunotherapy has revolutionized traditional tumour treatment. However, effective treatments for patients exhibiting αPD-1 resistance are still lacking. In our study, a combination of cytosine-phosphate-guanine oligodeoxynucleotides (CpG-ODNs), anti-OX40 and cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) injection in situ systematically generated a robust antitumour immune response in TC1 and B16 cells, which are αPD-1-resistant malignancies. More precisely, this method activates both adaptive and innate immunity. Additionally, in situ vaccination with CpG/αOX40/cGAMP fully activates the production of cytokines. However, the combination of αPD-1 does not improve the efficacy of triple therapy, prompting further questions. Collectively, the combination of CpG/αOX40/cGAMP causes the regression of various αPD-1-resistant tumours through the full mobilization of innate and adaptive immunity. In addition, we explored the therapeutic effect of triple therapy on the αPD-1-sensitive cell line CT26. The results showed that triple therapy could significantly enhance the therapeutic effect of αPD-1, and some mice even achieved complete tumour regression after the combined application of αPD-1 and triple treatment.","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"1597-1609"},"PeriodicalIF":5.8,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39586839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. 第十七届癌症生物免疫治疗年度NIBIT(意大利肿瘤生物治疗网络)会议，2019年10月11-13日，意大利维罗纳。

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-07-01 Epub Date: 2021-11-09 DOI: 10.1007/s00262-021-03104-1

Matteo Bellone, Marco Bregni, Vincenzo Bronte, Stefano Ugel, Pier Francesco Ferrucci, Massimo Di Nicola, Paola Nisticò, Gaia Zuccolotto, Antonio Rosato, Vincenzo Russo, Antonio Sica, Mario P Colombo

引用次数: 0

Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma. 非hcv /非hbv肝细胞癌患者循环免疫细胞和肿瘤浸润免疫细胞计数的高度差异

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-05-01 Epub Date: 2021-09-28 DOI: 10.1007/s00262-021-03061-9

Markus Bo Schoenberg, Tong Zhu, Jingcheng Hao, Julian Nikolaus Bucher, Xiaokang Li, Xinyu Li, Yongsheng Han, Dionysios Koliogiannis, Michaela Svihla, Markus Otto Guba, Jens Werner, Alexandr V Bazhin

{"title":"Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma.","authors":"Markus Bo Schoenberg, Tong Zhu, Jingcheng Hao, Julian Nikolaus Bucher, Xiaokang Li, Xinyu Li, Yongsheng Han, Dionysios Koliogiannis, Michaela Svihla, Markus Otto Guba, Jens Werner, Alexandr V Bazhin","doi":"10.1007/s00262-021-03061-9","DOIUrl":"https://doi.org/10.1007/s00262-021-03061-9","url":null,"abstract":"Background: Liver transplantation and liver resection are curative options for early hepatocellular carcinoma (HCC). The outcome is in part depended on the immunological response to the malignancy. In this study, we aimed to identify immunological profiles of non-HCV/non-HBV HCC patients.Methods: Thirty-nine immune cell subsets were measured with multicolor flow cytometry. This immunophenotyping was performed in peripheral blood (PB) and tumor specimens of 10 HCC resection patients and 10 healthy donors. The signatures of the highly differential leukocyte count (hDIF) were analyzed using multidimensional techniques. Functional capability was measured using intracellular IFN-γ staining (Trial Registration DRKS00013567).Results: The hDIF showed activation (subsets of T-, B-, NK- and dendritic cells) and suppression (subsets of myeloid-derived suppressor cells and T- and B-regulatory cells) of the antitumor response. Principal component analysis of PB and tumor infiltrating leukocytes (TIL) illustrated an antitumor activating gradient. TILs showed functional capability by secreting IFN-γ but did not kill HCC cells.Conclusions: In conclusion, the measurement of the hDIF shows distinct differences in immune reactions against non-HBV/non-HCV HCC and illustrates an immunosuppressive gradient toward peripheral blood.Trial registration: DRKS00013567.","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"1103-1113"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39468760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor. GHPA患者肠道菌群影响肿瘤的生长和PD-L1的表达。

IF 5.8

Cancer immunology, immunotherapy : CII Pub Date : 2022-05-01 Epub Date: 2021-10-13 DOI: 10.1007/s00262-021-03080-6

Ding Nie, Qiuyue Fang, Jianhua Cheng, Bin Li, Mingxuan Li, Hongyun Wang, Chuzhong Li, Songbai Gui, Yazhuo Zhang, Peng Zhao

{"title":"The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor.","authors":"Ding Nie, Qiuyue Fang, Jianhua Cheng, Bin Li, Mingxuan Li, Hongyun Wang, Chuzhong Li, Songbai Gui, Yazhuo Zhang, Peng Zhao","doi":"10.1007/s00262-021-03080-6","DOIUrl":"https://doi.org/10.1007/s00262-021-03080-6","url":null,"abstract":"Context: Pituitary adenoma (PA) is a common intracranial tumor. The evidence indicates that the tumor immune microenvironment (TIME) is associated with PA and that the intestinal flora influences other tumors' growth through interacting with the TIME. However, how the intestinal microbial flora contributes to the development of PA through the immune response is unknown.Objective and methods: Here we used high-throughput Illumina MiSeq sequencing targeting the V3-V4 region of the 16S ribosomal RNA gene to investigate the intestinal flora of patients with growth hormone-secreting pituitary adenoma (GHPA), nonfunctional pituitary adenoma (NFPA), and healthy controls. We determined their effects on tumor growth and the TIME. Fecal microbiota transplantation (FMT) was performed after adoptive transfer via peripheral blood mononuclear cells to tumor-bearing nude mice, which allowed the study of the immune response.Result: We discovered differences in the structures and quantities of intestinal flora between patients with GHPA, patients with NFPA, and healthy controls. After FMT, the intestinal flora of GHPA patients promoted the growth of tumors in mouse models. The number of programmed cell death ligand 1 (PD-L1)-positive cells increased in tumor tissues as well as the extent of infiltration of CD8+ cells. Increased numbers of CD3+CD8+ cells and increased levels of sPD-L1 were detected in peripheral blood.Conclusion: These findings indicated that the intestinal flora of patients with GHPA promoted tumor growth and that the immune system may mediate this change.","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":"1233-1245"},"PeriodicalIF":5.8,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39518912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6